

Subject Index

- ABC** Elite peroxidase kit, 53
- N*-Acetylation, 10
- Acetylcholine, 156, 161
- Acetylcholinesterase, 91, 156, 161
- ACTH** (adrenocorticotrophic hormone), 3, 10, 11
- CRF and secretion of, 60, 68, 75, 96, 97
- CRF-BP and, 81, 82, 91
- CRH and, 36-38, 51, 53
- as first peptide to affect brain, 4-5
- serotonin-CRF interaction and, 180
- Actinomycin, 135
- Activating protein 1 (AP-1), 22
- Activating transcription factor (ATF), 22
- Addiction, peptides and, 8-9
- Adenosine nucleotide ATP, 67, 69
- Adenylate cyclase (adenyl cyclase), 62, 63, 66-71, 169-71, 173, 178, 203-6, 208, 236
- Adrenal gland
- CRF-BP and, 86, 87
- CRH deficiency and, 54
- CRH synthesized in, 50
- NEP in, 145
- in postmortems of suicides, 99
- prohormone-processing in medulla of, 121, 122
- β -Adrenergic receptor, 233, 236
- Affective disorders, stress and, 43-44
- Affinity chromatography, 81, 125
- Agarose gel electrophoresis, 50, 52, 111
- AIDS, 43
- Aluminum, 7
- Alytesin, 227
- Alzheimer's disease
- CRF and, 90
- CSF CRF in, 100-103
- Amastatin, 115
- American Society of Biological Chemists, 1
- Amino acids
- bombesin-related peptide sequences of, 227-29
- CRF-BP and, 82, 83
- in CRF receptors, 62-64
- dermorphins and, 11
- NRD convertase sequences of, 109, 110
- number of, in peptides, 2
- Aminopeptidase M. *See* APM
- Aminopeptidase of the B type (Ap-B), 111-19
- cAMP, 136, 137, 142, 169, 171, 203
- Amphetamines, 177
- Amphiphilic helix, 91
- Amygdala
- CRF in, 71, 88, 96
- GRP mRNA in, 231
- Amygdaloid nuclei
- CRF in, 75
- galanin in, 193
- Amylin, 6
- β -Amyloid proteins, 6
- Amyotrophic lateral sclerosis, CSF CRF in, 101
- Analgesia
- of enkephalin, 19, 121, 132, 145
- morphine-induced, 25, 26
- Angiotensin, ix
- Anorexia, CCK-serotonin and induction of, 214-18
- Anorexia nervosa
- CRH dysregulation in, 36, 44
- CSF CRF in, 99-100, 103
- Anterior pituitary
- CRF-ACTH-glucocorticoid axis and, 60
- CRF in, 61, 67, 75, 96
- CRH synthesized in, 50, 51
- Antidepressants, serotonin and, 223
- Antiopeptide peptides, 7-9
- Anti-PC-KLH antibody response, 43
- Anxiety
- buspirone in treatment of, 177
- in CRH transgenic mice, 39-40, 44
- AP-1 (activating protein 1), 22
- APM (aminopeptidase M), 124, 157-58
- Appetite regulation
- CRH and, 57
- See also* feeding behavior
- Aprotinin, 113, 115
- Arcuate nucleus, serotonin and neuropeptides in, 179
- Arg, 106, 107, 111, 122-27, 135
- N*-arginine dibasic convertase, 107-11
- Arphamenines, 115
- Asparagine, 169
- Aspartate, 169, 236
- Aspartic proteinase, 127-28, 130
- Astrocytes, somatostatin overexpression in, 29-34
- ATF (activating transcription factor), 22
- Atrial natriuretic peptide, 114, 145, 179
- Atriopeptin, 156, 160
- AtT-20 cells, 135, 173
- Attention, in ACTH studies, 4-5
- Autonomic nervous system
- CRF and, 87
- spinal, neuropeptide-serotonin interactions in, 185-90

- autoradiographic localization of CRF receptors, 71-76
- Autoradiograms, 137
- Avoidance, in MSH/ACTH studies, 4
- AVP (arginine vasopressin), 6, 51, 53, 54, 66, 68, 69
- B** cells, in CRH transgenics study, 41-44
- Bacitracin, 199
- BARK (beta-adrenergic receptor kinase), 171-73
- Basal ganglia
CRF in, 96
in Huntington's disease, 101
- Basic residues, metalloproteinases with specificity for, 106-19
- BBB. *See* blood-brain barrier
- Becton-Dickinson FACStar Plus, 41, 42
- Behavior, neurochemical controls of, 218-19
- Benton Visual Retention Test, 5
- Benzodiazepine, 216
- Bestatin, 115
- Beta-adrenergic receptor kinase (BARK), 171-73
- Beta-galactosidase, PPEA and, 21
- Bio-Rad model 620 densitometer, 137
- Blood-brain barrier (BBB), 6-7
- Blood pressure
galanin and, 201-3, 207
NPY and, 132
- Bombesin (BN), ix, xi, 10
brain receptors of, 223-41
circadian rhythms and, 231-32
- Bombesin-like peptides, 156, 224-28
- Bone marrow, CRH overproduction and, 41, 42
- Bradykinin, 114, 156, 160
- Brain
bombesin receptors in, 223-41
CCK in, 223
CRF in, 60-62, 72, 75, 76, 97
serotonin and, 180
- CRF-BP in, 82, 86
biochemical analysis, 89-91
distribution, 87-88
gut and, 10-11, 62
NEP in, 145, 151, 153-54
NRD convertase in, 111
prohormone convertases in, 134
in response-to-novelty study, 164-66
serotonin in, 177, 178, 180
galanin interactions, 193-208
See also blood-brain barrier
- Bulimia, serotonin and, 177
- Buspiron, 177, 223
- C**-terminal peptides, 10
- Calcitonin, 62
- Calcitonin gene-related peptide. *See* CGRP
- CALLA antigen, 156, 160
- Capillary depletion method, 7
- Captopril, 115
- Carboxypeptidase E, 91, 107
- Carcinoma, rat thyroid, PC proteases and, 135
- Cardiovascular system
galanin-serotonin interactions in, 199-203
See also heart
- Carp urotensin, 90
- Casein kinase II, 63
- Casomorphin, 9
- CAT (chloramphenicol acetyltransferase), 20-24
- Catecholaminergic pathways, CRH and, 57
- Catecholamines, 51
- Caudal linear nucleus, CRF in, 75
- CCK. *See* cholecystokinin
- CD10, 160
- CD43, 41-42
- Cerebellum
CRF in, 61, 62, 75
NRD convertase in, 111
- Cerebral cortex
CRF-BP in, 87
CRF in, 61, 62, 71, 96
CRH synthesized in, 49-51
GRP in, 237
serotonin and neuropeptides in, 179
- Cerebrospinal fluid. *See* CSF
- CFP-AAF-pAB, 118
- CGRP (calcitonin gene-related peptide), 179-81
- Chemical affinity cross-linking studies, 62
- Chemotherapy, serotonin antagonists and, 177
- Childbirth, POMC as predictor in, 10
- Childhood leukemia, 156
- Chinese hamster ovary (CHO), 90, 170, 237-40
- Chloramphenicol acetyltransferase (CAT), 20-24
- Chlordiazepoxide, 44
- p-Chloroamphetamine, 180
- Cholecystokinin (CCK), ix, xi, 8, 10, 135-36, 142-43, 180-81
CNS action of, 223-24
receptor subtypes of, 214
in serotonergic modulation of feeding behavior, 213-19
- Cholera toxin, 236
- Chromatin granules, proenkephalin-processing enzymes in, 121-32
- Chromatography. *See* affinity

- chromatography; HPLC; Sephacryl S200 chromatography
- CI-988, 223, 224
- Circadian rhythms
 - bombesin and, 231-32
 - CRH and, 57
- Circumventricular organs (CVOs), 7
- pCMB, 113
- pCMPS, 113
- CNS (central nervous system)
 - CCK responses in, 223-24
 - CRF-BP in, 87
 - CRF in, 75, 76, 96
 - CRH distribution and role in, 36, 57, 60
 - literature on peptide action on, 1-2, 7
 - NEP in, 145, 156
 - neuropeptide effects on, 11
 - serotonin in, 176-78, 180-81
 - trophic effects of somatostatin in, 32
 - See also* autonomic nervous system; blood-brain barrier
- Concanavalin A-Sepharose, 126
- Corticosteroids, PC proteases and, 135
- Corticosterone
 - CRH and, 37, 38, 54-56
 - fluoxetine and, 180
- Corticotropin-releasing factor. *See* CRF
- Corticotropin-releasing hormone. *See* CRH
- Cortisol, 38, 86, 87, 96-99
- COS cells, 66, 82, 170-71
- CRE (cyclase responsive element), 22, 23
- CREB (cyclase responsive element-binding protein), 23
- CRF (corticotropin-releasing factor), ix-xi, 1
 - cerebrospinal fluid studies of, 96-103
 - discovery of, 96
 - effects of administration of, 60-61
 - functions of, 76
 - in MSH neonate studies, 5
 - postmortem studies of, 96-103
 - receptor subtypes of, 60-76
 - autoradiographic localization, 71-76
 - CRF₁, 62-63
 - CRF₂, 63
 - nomenclature, 65
 - pharmacological characteristics, 66-71
 - splice variants, 63-65, 75-76
 - serotonin interactions with, 180
- CRF-binding protein (CRF-BP)
 - in human plasma, 86-87
 - map of human gene, 84-85
 - membrane anchorage by, 91
 - modulatory actions of, 81-92
 - pharmacology of, 85-86
- CRH (corticotropin-releasing hormone), 6
 - description of, 36-37, 49-50
 - overproduction of, in transgenic mice, 36-44
 - production of mice deficient in, by targeted mutation, 49-57
- CSF (cerebrospinal fluid)
 - peptide in, 7
 - studies of CRF in, 96-103
- CMV (cytomegalovirus), 66
- Cushing's syndrome (Cushing's disease), 37, 38, 44, 86
- CVOs (circumventricular organs), 7
- Cyclase responsive element. *See* CRE
- Cyclase responsive element-binding protein (CREB), 23
- Cyclo(His-Pro), 6
- Cyclosporine, 6
- Cysteine, 109, 113, 115, 123, 129, 130, 233
 - in CRF-BP precursor, 82
- Cytomegalovirus (CTV), 66
- D**A. *See* dopamine
- DAMGO, 173
- Deglycosylation, 62, 233
- Delta opiate receptors, 168-73
- Delta sleep-inducing peptide (DSIP), 6
- Dementia
 - CRF and, 90, 91
 - CSF CRF in, 97, 101
- Dentate gyrus, NMB mRNA in, 231
- Depression
 - CRF in, 91, 96
 - CRH dysregulation and, 36-37, 44
 - CSF CRF in, 97-99
 - serotonin and, 177
- Dermorphins, 11
- Desipramine, 99
- Devazepide, 215-18, 224
- Dexamethasone suppression test (DST), 98
- Diacylglycerol, 236
- Digiscan open-field activity monitor system, 32, 33
- 5,7-Dihydroxytryptamine, 179
- Disulfide loops, 82, 84-85
- Dithiothreitol, 113, 115
- DMSO, 136
- cDNAs, ix
- mDNAs, ix
- Dopamine (DA), 10, 26, 91, 223
 - haloperidol as blocker of, 21
 - PC proteases and, 135
 - in response-to-novelty study, 164
- Dorsal motor nucleus of the vagus, CRF in, 96
- Dorsal root ganglion, NMB mRNA in, 231
- Drosophila, insulinase of, 109
- Drug addiction, peptides and, 8-9
- DSIP (delta sleep-inducing peptide), 6
- DST (dexamethasone suppression test), 98

DTT, 113, 127
 Duodenum, CRF-BP and, 86
 Duralon-UV Membrane, 136
 Dynorphin A, 6, 107, 168, 169

E-64c, 129
 E2078, 6
 Ebiratide, 6
 ECT (electroconvulsive therapy), CSF CRF
 after, 98
 Edman degradation, 82
 EDTA, 113, 115
 EGTA, 126, 239
 Electroporation, 157
 Embryonic stem cells. *See* ES cells
 Emesis, serotonin antagonists for, 177
 Endolysin-C, 109
 Endometrium, NEP in, 145
 Endopeptidases, 107, 109. *See also* NEP
 Endoproteases, basic residues and, 106-18
 β -Endorphin, 10, 96
 in MSH neonate studies, 5
 Endothelin-converting enzymes, 156
 Endothelins, 156, 160
 Endotoxin lipopolysaccharide, 157, 159
 ENKCRE sites, 20, 22, 23
 Enkephalin, ix, 7, 114, 135, 156, 160, 168,
 181
 as analgesic, 19, 121, 132, 145
 processing of proenkephalin to, 121-32
 See also proenkephalin
 Enkephalinase, 160
 Entorhinal cortex, galanin in, 203-6
 Enzymes
 basic residues study of, 106-19
 proenkephalin-processing, in chromaffin
 granules, 121-32
 Ep453, 130
 ES cells (embryonic stem cells), 157
 targeted mutation in, 49-57
Escherichia coli
 expression of PE in, 123
 protease III of, 109
 Esterases, intracellular, 130
 Estrogen-receptor half-sites, 85
 Ethanol addiction, 7
 Ethidium bromide staining of gels, 52
 European Neuropeptide Club, 3
 Exons, 82, 84-85, 91, 145-53, 158
 Exopeptidase, Ap-B as source of, 111

Farnesyl, 91
 Feeding behavior, CCK modulation of sero-
 tonergic control of, 213-19
 Fenfluramine, 177, 178
d-Fenfluramine, 216-17
dl-Fenfluramine, 218

First International Symposium on Mamma-
 lian Peptides, 11
 Fluoxetine, 99, 177, 180, 217
 Fluvoxamine, 177
 FMRFamide, 8
 Formamide, 136
 Forskolin, 128-30, 170, 171, 203, 205
 Freund's adjuvant, 21, 43
 Frogs, bombesin in, 10, 11, 224
 Furin, 134, 136-37

G protein-coupled receptors, 62, 63, 76,
 168-73, 203, 205, 208, 228, 233, 236
 GABA, 10, 91, 230
 D-Galactosamine, 159, 160
 Galanin, ix, 180, 181
 serotonin interactions with, in brain,
 193-208
 subtypes of, 196, 205, 207, 208
 Ganciclovir, 52, 157
 Gastric emptying, 5-HT-CCK interactions
 and, 218
 Gastrin-releasing peptide. *See* GRP
 Gel filtration, 81
 Geneticin, 157
 Geranylgeranyl, 91
 Glial fibrillary acidic protein (GFAP), 32, 34
 Glucagon, ix, 62
 Glucocorticoids
 CRF and secretion of, 87
 CRH and, 38, 49, 57, 60
 Glutamate, 230
 Glutathione, 6
 N-Glycanase, 82
 Glycerol, 113
 Glycosylation sites, 62-63, 82, 83, 110, 233
 Golgi apparatus, 106
 Granisetron, 177
 Granule cells, CRF in, 75
 Growth hormone releasing factor, 62, 68
 GRP (gastrin-releasing peptide), 10, 135,
 224, 227, 230, 233, 234, 236, 238, 239
 amino acid sequences of, by type of ani-
 mal, 227
 GRP-preferring receptors (GRP-R), 227-28
 GTP, 169-70, 236
 Guanine nucleotide-binding proteins,
 66-67, 236
 Guinea pigs, BBB in, 6
 Gut
 CRF in, 75
 CRH synthesized in, 50
 influence on brain from, 10-11, 62
 NEP in, 145

Haloperidol, 21, 101

- Heart
 - CRF in, 75
 - CRH synthesized in, 50
 - See also* cardiovascular system
- HEC (human enkephalin CAT), 20-23
- Helisoma* buccal ganglion neurons, 29
- Hemorphin, 9
- Heptapeptide dermorphins, 11
- HER (human enkephalin rat), 20, 23-24
- High-performance liquid chromatography. *See* HPLC
- Hippocampus
 - CRF in, 71, 75, 96
 - GRP in, 231, 237
 - NRD convertase in, 111
 - PPEA and CAT activities in, 21
 - serotonin in, 179
 - galanin interactions, 194-96, 198-99, 203-8
- History of neuropeptide research, 1-11
- HIV peptide, 111, 114
- Hot-plate test, 25, 26
- HPA axis (hypothalamic-pituitary-adrenal axis)
 - CRF and, 96, 103
 - CRF-BP and, 87
 - CRH and, 36-38, 41, 44, 52-57
 - DST measure of hyperactivity of, 98
- HPLC (high-performance liquid chromatography), 7, 81, 114
- 5-HT. *See* serotonin
- Human enkephalin CAT (HEC), 20-23
- Human enkephalin rat (HER), 20, 23-24
- Huntington's disease, CSF CRF in, 101
- HXXEH pentapeptide, 109
- Hyaline membrane disease, 57
- 5-Hydroxyindoleacetic acid, 194
- p*-Hydroxymercuribenzoate, 127
- 5-Hydroxytryptamine. *See* serotonin
- 5-Hydroxytryptophan, 180
- Hypothalamic-pituitary-adrenal (HPA) axis. *See* HPA axis
- Hypothalamo-hypophyseal portal system, 96
- Hypothalamus
 - CRF in, 96
 - CRH in, 50, 51, 71, 72, 74, 75
 - galanin in, 193-94, 203-5
 - NRD convertase in, 111
- I**BMX, 136-42
- IDE (insulin-degrading enzyme), 109
- IML (intermediolateral cell column), neuro-peptide-serotonin interactions in, 185-90
- Immune system
 - CRF and response to stress by, 61
 - CRH overproduction and, 40-43
 - CRH synthesized in, 50
 - stress and pathology of, 43-44
- Immunocytochemistry, 231
- Immunoglobulins, regulation of, 85
- Immunohistochemistry, 87, 118
- INF-1, 85
- Infants. *See* neonates
- Inflammation
 - CRF-BP and, 86
 - NEP in, 156, 160
 - vascular, in migraine, 180
- Inflammatory diseases, vulnerability to, CRF and, 91
- Inositol phospholipids, 203
- Inositol triphosphate, 239
- In situ* hybridization, 38, 71-75, 87, 111, 153-54, 231
- Insulin, 6
- Insulinase, 109
- Insulin-degrading enzyme (IDE), 109
- Insulin-like growth factor-binding proteins (IGF), 91
- Insulysin, 109
- Interferon gene, regulation of, 85
- Interleukins, regulation of, 85
- International Neuropeptide Society, 3
- Intestine. *See* gut
- Introns, 82, 84-85, 91, 145, 158
- Intron-spanning primers, 52
- IPN (interpeduncular nucleus), CRF in, 75
- Isoleucine, 236
- J**oints, CRF-BP and, 86
- Journals on peptides, 2-3, 11
- K**appa opiate receptors, 168-69, 171-73
- Ketanserin, 215
- KEX2, 107
- Keyhole-limpet hemocyanin (PC-KLH), 42
- Kidney, NEP in, 145-53, 156
- Kjell blood group antigen, 156
- Knockout mice (KO mice), ix, x
 - in CRH study, 52-57
 - in NEP study, 159
- Kozak consensus sequence, 83
- L**ateral septal nuclei, CRF in, 72-74
- Leucine, 7, 226
- Leu-enkephalin, 6
- Leukemia
 - childhood, 156
 - lymphoblastic, 146, 160
- Leukocytes, polymorphonuclear, 156
- Leupeptin, 113
- Levorphanol, 169
- LFA1 protein, 82
- LFB1 protein, 82

- LHRH (luteinizing hormone-releasing hormone), 6
- Ligand immunoradiometric assay (LIRMA), 86
- β -lipotropin, 10
- LIRMA (ligand immunoradiometric assay), 86
- Literature of neuropeptide research, 1-2, 7
- Litorin, 227, 230
- Liver, CRF-BP and, 82, 86
- Locus caeruleus, 223
- CRF in, 71, 96
- LPS (lipopolysaccharide), 157, 159-60
- LRE mice, 23-24
- LtK cells, 66
- Lung
- CRF-BP and, 86
- CRF in, 75
- CRH synthesized in, 50, 51
- glucocorticoids and maturation of, 57
- NEP in, 145, 151, 153-54
- Luteinizing hormone-releasing hormone (LHRH), 6
- Lymphatic system, NEP and, 160
- Lymphoblastic leukemia, 146, 160
- Lys, 106, 107, 111, 123-27, 135
- M**agnesium acetate, 113
- Mania, CSF CRF in, 101
- MAP (mitogen-activated protein), 237
- Medulla oblongata, galanin in, 197
- Melanocyte-stimulating hormone. *See* MSH
- Memory cells in CRH overproduction study, 43, 44
- Mercuric chloride, 127
- Metallopeptidases
- NEP in family of, 156
- new, 106-19
- Met-enkephalin, 7, 24
- in MSH neonate studies, 5
- Metergoline, 214
- Methionine, 83, 227
- Methiothepin, 205, 206
- Mianserin, 215
- Mice
- CRF-BP location on chromosome 13 of, 84-85
- CRF receptors in, 62, 63, 65
- NEP study of, 156-61
- opiate receptor in, 171-73
- PC protease study in, 135
- See also* knockout mice; LRE mice; transgenic mice; wild-type mice
- Midbrain, CRF in, 75
- MIF-1 (MSH release-inhibiting factor number 1), 1, 2, 6, 8
- in MSH neonate studies, 5
- Migrane, sumatriptan in, 177, 179-80
- Mitogen-activated protein (MAP), 237
- Mitosis, somatostatin inhibition of, 29
- MK 678, 173
- Morphiceptin, 9
- Morphine, 8, 168, 173
- in THM transgenic mice, 25
- Morphine pellet implantation, 26
- MORs. *See* mu opiate receptors
- MSH (melanocyte-stimulating hormone), 2, 8
- ACTH and, 4-5, 11
- BBB and, 6
- concepts involving (table), 5
- MSH release-inhibiting factor number 1 (MIF-1), 2
- α -MSH, 10
- Mu opiate receptors (MORs), 168, 169, 171-73
- proenkephalin and, 19-26
- Myristate, 91
- N**alm-6 cells, 145-46, 148
- Naloxone, 25, 173
- β -Naphthylamide (β -NA), 111-13
- National Center for Biotechnology Information, 22
- Nausea, serotonin antagonists for, 177
- NEM, 109, 113, 115
- Neomycin, 52, 158
- Neonates
- CSF CRF concentrations in, 97
- MSH effects in, 5
- NEP (neutral endopeptidase 24.11; neprilysin), 145-55
- septic shock modulated by, 156-61
- Neprilysin. *See* NEP
- Neuroepithelioma, 135
- Neurofilament (NF), 31
- Neurointermediate lobe of pituitary, CRF in, 61, 67
- Neurokinin A (NKA), 114, 181, 185-89
- Neurokinin B (NKB), 186
- Neurokinins, ix
- Neuroleptics, 21
- Neuromedin B (NMB), 224, 227, 228, 230, 233, 235-40
- Neuromedin C (NMC), 10, 230, 232-34, 238
- Neuropeptides
- biosynthesis model for, 121-32
- definition of, 5
- NEP control of, 156
- proprotein convertases and, 135
- serotonin interactions with, 176-81
- galanin interactions in brain, 193-208
- in spinal autonomic systems, 185-90
- Neuropeptide Y (NPY), ix, 132, 135, 179, 180, 201

Neurotensin, ix, 114, 181, 223
 and behavioral response to novelty, 164-66
 Neurotransmitters, multiple, in one neuron, 181
 Neutral endopeptidase 24.11. *See* NEP
 NF (neurofilament), 31
 NF-kappa-B, 85
 Nicotine withdrawal, CRF in, 91
 Nissl counterstaining, 53, 54
 NKA. *See* neurokinin A
 NKB. *See* neurokinin B
 NMB. *See* neuromedin B
 NMC. *See* neuromedin C
 Noradrenaline, 203, 223
 Norepinephrine, 91, 179, 230
 Northern blot analysis, 38, 111, 136-37, 139, 158
 Novelty, behavioral response to, 164-66
 NPY, 10. *See* neuropeptide Y
 NRD convertase, 107-11
 Nucleus accumbens
 CRF in, 71
 in response-to-novelty study, 164, 165
 Nucleus of the solitary tract, CRF in, 71
O
 Obesity
 CRF in, 91
 serotonin releaser vs., 177
 Obsessive-compulsive disorder, serotonin and, 177
 8-OH-DPAT, 198-206, 208, 213, 215
 Olfactory bulb
 CRF in, 71
 NMB mRNA in, 231
 Oligonucleotides, 109, 126
 Oligosaccharide chains, 233
 Ondansetron, 177
 Opiate alkaloids, 8, 168
 Opiate peptides, 7-9. *See also* opiate receptors
 Opiate receptors
 delta, 168-73
 desensitization of, 170-73
 effector coupled, 168-73
 G protein coupled, 62, 63, 76, 168-73
 kappa, 168-69, 171-73
 mu (MORs), 168, 169, 171-73
 proenkephalin and, 19-26
 Opioid, definition of, 8
 Optovarimex-3, 25
 Ovary
 Chinese hamster (CHO), 90, 170, 237-40
 CRH synthesized in, 50
 PC4 in, 134
 Ovine peptides, CRF-BP and, 85, 87
 Oxytocin (OT), ix, 6, 51, 75

P
 P₂₅ peptide, 111, 114
 PACAP27, 6
 PACAP38, 6
 PACE4, 134
 Pain
 chronic, CSF CRF in, 97
 NEP and, 160
 See also migraine; opiate peptides; opiate receptors
 Palmitate, 91
 Palsy, progressive supranuclear, CSF CRF in, 101
 Pancreas
 CRF-BP and, 86
 PC proteases in, 135
 Pancreatic polypeptide, 6
 Panic disorder, CSF CRF in, 101
 Parathyroid hormone, 62
 Paraventricular nucleus. *See* PVN
 Parkinson's disease, CSF CRF in, 101
 Paroxetine, 177
 PBS (phosphate-buffered saline), 53
 PC1/3 protease, 122, 125-27, 130-32, 134-42
 PC2 protease, 122, 125-27, 130-32, 134-37, 139, 141, 142
 PC4 protease, 134
 PCS/6 protease, 134
 PCE (POMC-converting enzyme), 127
 PC-KLH (keyhole-limpet hemocyanin), 42
 PCMB, 115
 PCMPS, 115
 PCR (polymerase chain reaction), 82, 148-49, 153
 reverse-transcription, 38, 50, 52
 PE. *See* proenkephalin
 Pentagastrin, 223
 Pentylenetetrazol (PTZ), 21
 Pepstatin, 115
 Pepstatin A-agarose, 126
 Peptide hormone precursors, 106
 Peptide mapping studies, 62
 Peptide-MCA substrates, 124, 126
 Peptides
 definition of, 2
 journals on, 2-3, 11
 nomenclature of, 2
 Peptide T, 6
 Peptide transport system-1 (PTS-1), 6
 Peroxidase staining, 53, 54, 117
 Pertussis toxin, 169, 170, 236-37
 PFC (plaque-forming cells), in CRH transgenics study, 43
 Pgg (phosphoglycerate kinase-1), 52
 o-Phenanthroline, 113, 115
 Phenylalanine, 226

- Phenylmethylsulfonyl fluoride, 113
 Phe-Pro-Leu-Gly-NH, 6
 Phosphate-buffered saline (PBS), 53
 Phosphatidylinositol, 91
 Phosphocholine, 42
 Phosphodiethyl 03, 115
 Phosphoglycerate kinase-1 (pgk), 52
 Phospholipase, 239, 240
 Phospholipase C, 178, 205, 236, 239
 Phosphoramidon, 158-59
 Phyllostin, 226, 227
 Pigs
 galanin in brains of, 196
 GRP in, 10
 Pitrilysin, 109
 Pituitary
 cloning of CRF₁ receptor from, 63
 CRF-BP distribution in, 87
 in depression, 99
 proprotein convertase mRNA in, 135
 See also anterior pituitary; neurointermediate lobe of pituitary
 Pituitary adenylate cyclase-activating peptide, 62
 PKC (protein kinase C), 63, 136
 Placenta, CRF-BP and, 86
 Plaque-forming cells. *See* PFC
 PMA, 136-42
 PMSF, 115
 pPNT, 52
 Polyacrylamide gel electrophoresis, 112, 113
 Polyadenylation sites, 151
 Polymerase chain reaction. *See* PCR
 Polypeptides, definition of, 2
 POMC (pro-opiomelanocortin), 9-10, 53, 67, 76, 96, 127, 130, 132, 134
 POMC-converting enzyme (PCE), 127
 Postpartum depression, CRF in, 91
 Posttraumatic stress disorder, CRF in, 91
 PPEA (preproenkephalin A), 20-24
 Preeclampsia, CRF-BP and, 87
 Pregnancy, human
 CRF-BP in, 86, 87
 steroid administration during, 57
 Preproenkephalin A (PPEA), 20-24
 Primer extension analysis, 82
 Prodynorphin, 9-10, 135
 Proenkephalin (PE), 9-10, 135
 mu opiate receptors and, 19-26
 Proenkephalin-processing enzymes in chromatin granules, 121-32
 Proglucagon, 135
 Progressive supranuclear palsy, CSF CRF in, 101
 Prohormone convertases, 122, 134-43
 Prohormones, 108
 enzymes for processing of, 121-32
 future drugs to target, 131-32
 proteolytic processing of, 106
 Prohormone thiol protease. *See* PTP
 Proinsulin, 135
 Pro-Leu-Gly-NH₂. *See* MIF-1
 Proneuropeptide Y (pro-NPY), 130, 132
 Pro-opiomelanocortin. *See* POMC
 Propeptides, 227
 Prosomatostatin, 107, 134
 Protease III, 109
 Proteases
 in converting prohormones to neuropeptides, 121-32
 inhibitors of, 113, 199
 PTP, 122-32
 Protein kinase A, 63
 Protein kinase C. *See* PKC
 Proteins, definition of, 2
 Proteolysis
 basic residues and, 106-19
 definition of, 106
 in PE processing in chromatin granules, 122-32
 PTP (prohormone thiol protease), 122-32
 PTS-1 (peptide transport system-1), 6
 PTZ (pentylentetrazol), 21
 Purkinje cells, CRF in, 75
 PVN (paraventricular nucleus)
 bombesin response in, 230-32
 CCK-induced enhanced 5-HT activity in, 216
 CRF in, 96
 CRH in, 49, 53, 60, 72, 75
 GRP receptor antagonist in, 233
 serotonin-CRF interactions in, 180
 Pyroglutamate, 227
Quinpirole, 216
Rabbit polyclonal ACTH antiserum, 54
 RACE technique, 146
 Radioimmunoassay. *See* RIA
 Radioligand binding, 61, 66, 178, 231
 Ranatensin, 224, 226, 227
 Raphe nuclei
 BN-CCK-serotonin interactions in, 224-26
 CRF in, 75
 GRP receptor antagonist in, 233
 pharmacology of bombesin in, 230
 serotonin and, 177, 186, 223
 CCK study, 215
 Rat enkephalin CAT. *See* REC
 Rats
 Ap-B in, 111-12
 BBB in, 6
 bombesin-receptor study of, 223-41

- CCK and 5-HT studies in feeding behavior of, 214-18
- CRF-BP in, 82, 83, 87-88
- CRF receptors in, 62, 63, 65-69, 71
- in MSH/ACTH studies, 4-5
- NEP in, 145-55
- NRD convertase in, 107, 109, 111, 116-19
- opiate receptor in, 171, 173
- proprotein convertase mRNA in, 135
- in response-to-novelty study, 164-66
- serotonin and neuropeptides in, 179, 180
- serotonin-galanin brain interactions in, 193-208
- RC121, 6
- RC160, 6
- RC161, 6
- REC (rat enkephalin CAT), 20, 21, 23-24
- Rhesus monkeys, CSF CRF concentrations in, 97
- Rhodopsin, 233
- RIA (radioimmunoassay), 6, 231
- Ribonuclease, 151
- RNAid Plus Kit, 136
- mRNAs
- NEP, 145-55
 - prohormone convertase, 134-43
- RNase protection assays, 72, 150-53
- Ryanodine, 239
- S**
- Salmonella enteritidis*, 157, 159
- Satiety, 5-HT-CCK interactions and induction of, 213-19
- Sauvagine, 66, 69, 70, 90
- Scatchard analysis, 61, 100
- Schizophrenia, CSF CRF in, 97, 98, 101
- SDS PAGE, 81, 127, 130
- Second messengers, prohormone convertase mRNA modulation by, 134-43
- Secretin, 62
- Sephacryl S-200 chromatography, 87, 125, 126
- Septic shock, NEP modulation of, 156-61
- Serine protease, 113, 115
- Serotonin (5-HT; 5-hydroxytryptamine), x-xi, 7, 75, 91
- mechanisms and functions of neurons of, 176-81
 - neuropeptides and, 176, 179-81
 - galanin interactions in brain, 193-208
 - in spinal autonomic systems, 185-90
 - in psychiatric disorders, 223
 - receptor subtypes of, 178, 181, 205-8, 223
 - feeding behavior and, 213-19
- Serotonin behavioral syndrome, 179
- Sertraline, 177
- Sex differences
- in attention, MSH studies, 5
 - in CRH-deficient mice, 54-56
 - in somatostatin study of transgenic mice, 32, 34
- Sheep, CRF-BP in, 89
- Shock. *See* septic shock
- Skeletal muscle, CRF in, 75
- Sodium dodecyl sulfate, 136
- Somatization disorders, CSF CRF in, 101
- Somatostatin (SST), ix, 6, 114, 179, 181
- pro- (somatostatin-28), 107, 114
 - as trophic factor, 29-34
- Somatostatin receptor. *See* SSTR1
- Southern blot analysis, 51
- SP. *See* substance P
- Spinal autonomic systems, neuropeptides and serotonin in, 185-90
- Spinal cord
- CRF-BP and, 86
 - NEP in, 145, 151, 153-54
 - neuropeptides and, 11
 - PPEA and, 21
- Spinal trigeminal nucleus, serotonin and neuropeptides in, 179
- Spleen
- CRF in, 61, 87
 - CRH overproduction and, 41-43
 - CRH synthesized in, 50
- SRIF, 169
- SST. *See* somatostatin
- SSTR1 (somatostatin receptor), 169-70
- Stomach
- CRF-BP and, 86
 - See also* feeding behavior
- Stress
- CRF and, 60-61, 91, 96
 - CRH and, 36, 39-44, 54-57, 60
 - PTS-1 and, 7
- Stria terminalis, CRF in, 75, 180
- Substance P (SP), ix, xi, 114, 145
- and behavioral response to novelty, 164-66
 - in migraine, 179-80
 - serotonin-CRF interaction and, 180, 185-89
- Substantia nigra
- galanin in, 197
 - neurotensin and, 223
 - NRD convertase in, 111
 - in response-to-novelty study, 164-66
- Subtilisin, 118, 122, 125
- Suicide
- CSF CRF concentrations in, 97, 99, 100
 - serotonin and, 177
- Sulfhydryl reagents, 109
- Sumatriptan, 177, 178, 179-80
- Summer Neuropeptide conferences, ix-xi, 1
- Suprachiasmatic nucleus (SCN)

- bombesin response in, 230-32
 GRP receptor antagonist in, 233
 GRP receptors in, 231
 serotonin and neuropeptides in, 179
 Swiss 3T3 cells, 227-28, 236
- T**
 Tachykinins, ix, 156, 160, 186, 223
 Tail-flick test, 25
 Tardive dyskinesia, 21
 Targeted mutation, CRH-deficient mice produced by, 49-57
 TATA box, 82, 147, 148
 TCA (trichloroacetic acid), 125
 Testis
 Ap-B in, 111-12
 in CRH overproduction study, 38
 CRH synthesized in, 50
 NEP in, 151, 153
 NRD convertase in, 109, 111, 116-19
 PC4 in, 134
 PPEA and CAT in, 21-24
 Tetrapeptides, 6
 Thimet oliopeptidase, 115
 Thiorphan, 156
 THM (tyrosine hydroxylase mu opiate receptor), 20, 24-26
 Thymidine kinase (TK), 52
 Thyroid, PC proteases and, 135
 TK (thymidine kinase), 52
 TNF α , 159-61
 TPCK, 115
 Transcription factor data base, 22
 Transgenic mice, ix, x
 CRH-deficient, produced by targeted mutation, 49-57
 CRH overproduction in, 36-44
 enkephalin and mu opiate receptors in, 19-26
 in NEP study, 158-59
 somatostatin study of, 29-34
 TRH (thyrotropin-releasing hormone), x-xi, 6, 180, 181, 185, 186, 188, 189
 Trichloroacetic acid (TCA), 125
 Tris-HCl buffer, 113
 Trophic factor, somatostatin as, 29-34
 Trypsin, 109
 Tumors, POMC in, 10
 Tyr-MIF-1, 1, 6, 8-9
 in MSH neonate studies, 5

- Tyrosine hydroxylase mu opiate receptor.
 See THM
 Tyrosine kinase, 236-37
 Tyrotropin-releasing hormone, in MSH neonate studies, 5
 Tyr-Pro-Leu-Gly-NH $_2$. See Tyr-MIF-1
 D-Tyr-Pro-Leu-Gly-NH $_2$, 6
 Tyr-W-MIF-1, 6, 8
- U**
 Urotensin, 90
 Urotensin I, 66, 69, 70
 UV Stratalinker, 136
- V**
 Vasoactive intestinal peptide. See VIP
 Vasopressin, ix, 4, 75
 arginine (AVP), 6, 51, 53, 54, 66, 68, 69
 Ventral di- and telencephalon, galanin in, 193-94
 Ventral limbic cortex, galanin in, 194-96
 Ventral pallidum, in response-to-novelty study, 164-66
 Ventral tegmental area. See VTA
 Ventromedial nucleus. See VMH
 Version 5.a, 3
 Violent aggressive behavior, serotonin and, 177
 VIP (vasoactive intestinal peptide), 62, 66, 68, 69, 179
 VMH (ventromedial nucleus)
 CCK in, 223
 CRF in, 72, 74, 75
 Voltage clamp recording, 234, 239, 240
 von Willebrand factor precursor, 134
 VTA (ventral tegmental area), in response-to-novelty study, 164-66
- W**
 WAY-100135, 213, 215
 Western blot analysis, 111, 129
 Wild-type mice (WT mice)
 CRH and, 52-56
 in NEP study, 156-57, 160
 Winter Neuropeptide Conference, 2
- X**
Xenopus oocytes, 228, 232, 238-40
- Z**
 Zinc-binding pentapeptide, 110
 Zinc metalloproteases, 160
 Zinc phosphate, 4
 Zn $^{2+}$ metalloproteinase, 109, 112-15, 118
 Zymogen activation, 106

Index of Contributors

Azaryan, A. V., 121-133

Bakke, A. C., 36-48
Banks, W. A., 1-18
Behan, D. P., 81-95
Blake, A., 168-175
Booze, R. M., 145-155
Brenner, M., 29-35
Bush, L., 164-167

Cadel, S., 106-120
Carroll, M. C., 156-163
Chalmers, D. T., 60-80
Chesneau, V., 106-120
Cho, H. J., 19-28
Cohen, P., 106-120
Cooper, S. J., 213-222
Crawley, J. N., ix-xi

Davis, T. P., 134-144
De Souza, E. B., 60-80, 81-95
Donovan, D. M., 19-28
Draoui, M., 106-120
Duncan, J. E., 36-48

Finco, O., 156-163
Foulon, T., 106-120
Fuller, R. W., 176-184
Fuxe, K., 193-212

Gerard, C., 156-163
Gerard, N. P., 156-163
Grigoriadis, D. E., 60-80

Hall, M. D., 223-243
Hanson, G., 164-167
Hartline, K. M., 96-105
Hedlund, P. B., 193-212
Heinrichs, S. C., 36-48
Helke, C. J., 185-192
Hersh, L. B., 145-155
Hook, V. Y. H., 121-133

Jacobson, L., 49-59

Kalivas, P. W., 164-167
Kastin, A. J., 1-18
Kolakowski Jr., L. F., 156-163
Kreek, M. J., 19-28

Law, S. F., 168-175
Li, C., 145-155
Liaw, C., 60-80
Lovenberg, T. W., 60-80
Lowry, P. J., 81-95
Lu, B., 156-163

Majzoub, J. A., 49-59
Mania-Farnell, B., 134-144
McLean, S., ix-xi
Messing, A., 29-35
Miner, L. L., 19-28
Muglia, L., 49-59

Nemeroff, C. B., 96-105
Nyberg, F., 19-28

Olson, R. D., 1-18
Owens, M. J., 96-105

Pinnock, R. D., 223-243
Potter, E., 81-95
Prat, A., 106-120

Reisine, T., 168-175
Reynolds, T., 223-243
Rittenberg, M. B., 36-48

Sawchenko, P., 81-95
Schiller, M. R., 121-133
Schwartz, J. P., 29-35
Sharpe, L., 19-28
Stenzel-Poore, M. P., 36-48

Takemura, M., 19-28
Tallent, M., 168-175
Taniwaki, T., 29-35
Tezapsidis, N., 121-133

Uhl, G. R., 19-28
Unterwald, E., 19-28

Vale, W. W., 81-95

Woodruff, G. N., 223-243

Yang, L., 185-192

Zadina, J. E., 1-18



